Teva, world’s largest generic drugmaker, says checkup related to request for approval of generic drug
Super-Sol sells 200m shekels of shares | Cellcom launches low-cost TV, internet, telephone service | Perrigo jumps on Einhorn’s long position | Tel Aviv gets lift from higher Wall Street
Teva executives among Israel’s highest-paid, but S&P keeps Teva at BBB, negative outlook | Haifa Chemicals asks to swap judge hearing ammonia appeal, says can’t supply solar field component.
Teva, the world's biggest generic drug maker, was left without a permanent chief last week after Erez Vigodman stepped down after missteps sent its shares to their lowest in more than 10 years.
Ousted CEO Erez Vigodman’s policy of acquiring competitors before they ate Teva ultimately left the Israeli drug company weaker.
A week after its CEO stepped down, drug maker exceeds analysts’ estimates for sales and profits in 2016's fourth quarter.
TA-25 and other TASE stalwarts give way to six new market measures.
Analysts and insiders call for wider shake-up of management and business strategy at the global pharma giant, Israel's biggest company.
Teva has faced numerous recent hurdles, including successful patent challenges to its most important branded product, the multiple sclerosis treatment Copaxone, and a U.S. investigation into generic drug price fixing.
Court rules Israeli pharmaceutical giant's patents for multiple sclerosis drug Copaxone no longer valid; cash flow could dip by 19%.